Influenza Vaccine Comparisons (2023−2024 Season)- MPR

Influenza Vaccine Comparisons

INFLUENZA VACCINE COMPARISONS (2023−2024 SEASON)
Storage and Handling
• Store refrigerated at 2–8°C (36–46°F) • Do not freeze; discard if product has been frozen • Protect from light • Do not use influenza vaccine beyond the expiration date printed on the label • Once punctured for the 1st dose, multidose vials should be discarded after the Beyond Use Date (BUD) or the maximum number of doses contained per vial. If no BUD, use the expiration date.
Brand	Indicated Age	Route	Allergies¹	Mercury content (mcg Hg/0.5mL)	How Supplied
INACTIVATED INFLUENZA VACCINE, QUADRIVALENT, ADJUVANTED (aIIV4)
Fluad Quadrivalent	≥65yrs	IM	egg protein, neomycin, kanamycin, hydrocortisone, formaldehyde, CTAB	0	0.5mL single-dose prefilled syringe
INACTIVATED INFLUENZA VACCINE, QUADRIVALENT, HIGH DOSE (HD-IIV4)
Fluzone High-Dose Quadrivalent	≥65yrs	IM	egg protein, formaldehyde	0	0.7mL single-dose prefilled syringe
INACTIVATED INFLUENZA VACCINE, QUADRIVALENT (IIV4), STANDARD DOSE
Afluria Quadrivalent	≥6mos	IM	egg protein, neomycin, polymyxin, hydrocortisone	24.5	5mL multi-dose vial²
Afluria Quadrivalent	≥3yrs			0	0.5mL single-dose prefilled syringe
Fluarix Quadrivalent	≥6mos	IM	egg protein, polysorbate 80, gentamicin, hydrocortisone, formaldehyde	0	0.5mL single-dose prefilled syringe
FluLaval Quadrivalent	≥6mos	IM	egg protein, polysorbate 80, formaldehyde	0	0.5mL single-dose prefilled syringe
Fluzone Quadrivalent	≥6mos	IM	egg protein, formaldehyde	25	5mL multi-dose vial
Fluzone Quadrivalent	≥6mos	IM	egg protein, formaldehyde	0	0.5mL single-dose prefilled syringe,³ 0.5 mL single-dose vial
INACTIVATED INFLUENZA VACCINE, QUADRIVALENT, CELL-CULTURE-BASED (ccIIV4)
Flucelvax Quadrivalent	≥6mos	IM		0	0.5mL single-dose prefilled syringe
				25	5mL multi-dose vial
LIVE, ATTENUATED INFLUENZA VACCINE, QUADRIVALENT (LAIV4)
FluMist Quadrivalent	2–49yrs	IN	egg protein, porcine gelatin, arginine, gentamicin, EDTA	0	0.2mL single-dose prefilled nasal spray
RECOMBINANT INFLUENZA VACCINE, QUADRIVALENT (RIV4)
Flublok Quadrivalent	≥18yrs	IM	polysorbate 20	0	0.5mL single-dose prefilled syringe
NOTES
Key: IM = intramuscular; IN = intranasal IM: For adults and older children, the recommended site of IM administration is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh. Specific guidance regarding site and needle length for intramuscular administration can be found in ACIP’s General Recommendations on Immunization. ¹ All persons aged ≥6mos with egg allergy should receive influenza vaccine and that any influenza vaccine (egg-based or nonegg based) that is otherwise appropriate for the recipient’s age and health status can be used. A history of severe allergic reactions (eg, anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any flu vaccine is a contraindication. ² May be administered by needle/syringe (≥6mos) or PharmaJet Stratis Needle-Free Injection System (18–64yrs only). Dose volume is 0.25mL (must be drawn from multi-dose vial) for 6–35mos and 0.5mL for ≥3yrs. ³ Fluzone Quadrivalent 0.25mL prefilled syringes are no longer available. If a prefilled syringe is used for the 6–35mos age group, use the 0.5mL syringe. Immunization providers should review FDA-approved prescribing information for 2022–2023 influenza vaccines for the most updated information, including (but not limited to) indications, contraindications, and precautions. Table listing reflects vaccines expected to be available during the 2022–2023 influenza season. This information is subject to change. For information on individual vaccines, see the product entries, contact the manufacturer, or call the National Immunization Hotline at (800) 232-4636.
REFERENCES
Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023–24 Influenza Season. MMWR Recomm Rep.2023;72(No. RR-2):1–25. DOI: http://dx.doi.org/10.15585/mmwr.rr7202a1 (Rev. 11/2023)

Want to read more?